State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai 200025, China.
Biomark Res. 2013 Aug 14;1(1):24. doi: 10.1186/2050-7771-1-24.
Lymphoid malignancies, mainly including lymphocytic leukemia and lymphoma, are a group of heterogeneous diseases. Although the clinical outcome of patients has been significantly improved with current immuno-chemotherapy, definitive biomarkers remain to be investigated, particularly those reflecting the malignant behavior of tumor cells and those helpful for developing optimal targeted therapy. Recently, genome-wide analysis reveals that altered genetic methylations play an important role in tumor progression through regulation of multiple cellular transduction pathways. This review describes the pathogenetic effect of the aberrant genetic methylation in lymphoid malignancies, with special emphasis on potential therapeutic strategies targeting key signaling networks.
淋巴恶性肿瘤，主要包括淋巴细胞白血病和淋巴瘤，是一组异质性疾病。尽管目前的免疫化疗已经显著改善了患者的临床预后，但仍需要研究明确的生物标志物，特别是那些反映肿瘤细胞恶性行为的生物标志物，以及有助于制定最佳靶向治疗的生物标志物。最近，全基因组分析表明，异常遗传甲基化通过调节多个细胞信号转导通路在肿瘤进展中发挥重要作用。本文描述了异常遗传甲基化在淋巴恶性肿瘤中的发病机制作用，特别强调了针对关键信号网络的潜在治疗策略。
